Sarilumab: Difference between revisions
(Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ===COVID=== ==Pediatric Dosing== ==Special Populations== ==...") |
No edit summary |
||
| Line 7: | Line 7: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[COVID]]=== | ===[[COVID]]=== | ||
*Use the single-dose, prefilled syringe (not the prefilled pen) for SQ injection<ref>https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults--therapeutic-management/</ref> | |||
*Reconstitute sarilumab 400 mg in 100 cc 0.9% NaCl and administer as an IV infusion over 1 hour<ref>https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults--therapeutic-management/</ref> | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Line 45: | Line 47: | ||
==Comments== | ==Comments== | ||
*Use as an alternative immunomodulatory drug if tocilizumab is not available or not feasible to use (BIIa). | |||
*In the United States, the currently approved route of administration for sarilumab is SQ injection. In the REMAP-CAP trial, the SQ formulation was used to prepare the IV infusion. | |||
==See Also== | ==See Also== | ||
Latest revision as of 21:05, 18 January 2022
Administration
- Type:
- Dosage Forms:
- Routes of Administration:
- Common Trade Names:
Adult Dosing
COVID
- Use the single-dose, prefilled syringe (not the prefilled pen) for SQ injection[1]
- Reconstitute sarilumab 400 mg in 100 cc 0.9% NaCl and administer as an IV infusion over 1 hour[2]
Pediatric Dosing
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
- Use as an alternative immunomodulatory drug if tocilizumab is not available or not feasible to use (BIIa).
- In the United States, the currently approved route of administration for sarilumab is SQ injection. In the REMAP-CAP trial, the SQ formulation was used to prepare the IV infusion.